

ChemBioChem

Combining Chemistry and Biology



European Chemical Societies Publishing



Accepted Article

Title: Building up Pt(II)-thiosemicarbazone-lysine-sC18 conjugates

Authors: Axel Klein, Alexander Haseloer, Tamara Lützenburg, Joss Pepe Strache, Jörg Neudörfl, and Ines Neundorf

This manuscript has been accepted after peer review and appears as an Accepted Article online prior to editing, proofing, and formal publication of the final Version of Record (VoR). This work is currently citable by using the Digital Object Identifier (DOI) given below. The VoR will be published online in Early View as soon as possible and may be different to this Accepted Article as a result of editing. Readers should obtain the VoR from the journal website shown below when it is published to ensure accuracy of information. The authors are responsible for the content of this Accepted Article.

To be cited as: ChemBioChem 10.1002/cbic.202000564

Link to VoR: https://doi.org/10.1002/cbic.202000564

WILEY-VCH

Building up Pt(II)-thiosemicarbazone-lysine-sC18 conjugates

Alexander Haseloer,^[a] Tamara Lützenburg,^[b] Joss Pepe Strache,^[a] Jörg Neudörfl,^[C] Ines Neundorf,^{[b],*}

and Axel Klein [a],*

[a] Universität zu Köln, Department für Chemie, Institut für Anorganische Chemie, Greinstraße 6, D-50939 Köln, Germany.

[b] Universität zu Köln, Department für Chemie, Institut für Biochemie, Zülpicher Str. 47a, D-50674 Köln, Germany.

[c] Universität zu Köln, Department für Chemie, Institut für Organische Chemie, Greinsstraße 4, D-50939 Köln, Germany.

*Correspondence: axel.klein@uni-koeln.de; Tel.: +49-221-470-4006;

ORCID: Alexander Haseloer 0000-0003-0480-7568, Tamara Lützenburg 0000-0003-0629-4022, Joss Pepe Strache 0000-0001-7321-8375, Jörg Neudörfl 0000-0002-2918-0565, Ines Neundorf 0000-0001-6450-3991, Axel Klein 0000-0003-0093-9619

Supplementary Information (SI) available: Figures showing crystal and molecular structures, cyclic voltammograms, HPLC-ESI MS spectrometry and results of the antiproliferative activity, alongside with tables containing structural data, NMR data, UV-vis absorption data, and electrochemical data. See DOI: xxx

ChemBioChem accepted

Three chiral tridentate N^N^S coordinating pyridine-carbaldehyde (S)-N4-(αmethylbenzyl)thiosemicarbazones (HTSCmB) were synthesised alongside with lysine-modified derivatives. One of them was selected and covalently conjugated to the cell-penetrating peptide sC18 by solid phase peptide synthesis. The HTSCmB model ligands, the HTSCLp derivatives and the peptide conjugate form rapidly and quantitatively, very stable Pt(II) chlorido complexes [Pt(TSC)Cl] when reacted with K₂PtCl₄ in solution. From one TSCmB model complex and the peptide conjugate complex the Pt(CN) derivatives were obtained through $Cl^- \rightarrow CN^-$ exchange. Ligands and complexes were characterised using NMR, IR spectroscopy, HR-ESI-MS and single crystal XRD.-Intriguingly, no decrease in cell viability was observed when testing the biological activity of the lysine-tagged HdpyTSCLp, its sC18 conjugate HdpyTSCL-sC18, or the PtCl and Pt(CN) conjugate complexes in three different cell-lines. Thus, given the facile and effective preparation of such Pt-TSC-peptide conjugates, these systems might pave the way for future use of late-stage labelling with Pt radionuclides and application in nuclear medicine.

Keywords: Thiosemicarbazone; Platinum; cell penetrating peptide; conjugates; antiproliferative

Introduction

Thiosemicarbazones (TSC) have been studied in the last 70 years with regard to their use as versatile ligands in coordination chemistry [1-17] with applications in transition metal catalysis,[1,4-6] and as materials for biomedical imaging and treatment.[5-17] TSCs of heterocycles, especially pyridine, form a vast group within the class of TSC. They can act as tridentate N^N^S chelate ligands forming stable complexes with many metals [1-3] and many studies have shown their cytotoxic behaviour with and without a coordinated metal ion.[14-20]

Many Pt(II) complexes, the most prominent being cisplatin, exhibit high anti-proliferative activity.[21-23] This holds also true for TSC and related Pt(II) complexes,[10-13,23-29] which affect even cisplatin resistant cells. It is assumed that they act with high activity by a different mode of action than cisplatin.[12,24,25]

However, although promising, metal complexes are generally only less developed as pharmaceutics owing to their poor water solubility and limited cellular uptake.[30] One way to overcome these issues is the combination of metal complexes with bioactive peptides with bioactive peptides, which has gained considerable attention during the last decade.[31-41] In this context, so-called cell penetrating peptides (CPPs) are promising tools to deliver metal complexes into various types of cells.[41-49] For instance, the Pt(IV) analogue of oxaliplatin was successfully conjugated to the CPP Tat(48-58) protein providing increased water solubility and bioavailability.[23,39,40]

Herein, we present the synthesis of three chiral (*S*)-*N*4-(α -methylbenzyl) thiosemicarbazone (HTSCmB) protoligands (ligand precursors prior to deprotonation upon coordination) and their lysine derivatives (HTSCL and HTSCLp). Moreover, the lysine-tagged di-2-pyridylketone TSC (HdpyTSCL) was successfully coupled to the recently described cell-penetrating peptide sC18 (Gly-Leu-Arg-Lys-Arg-Leu-Arg-Lys-Phe-Arg-Asn-Lys-Ile-Lys-Glu-Lys-NH₂),[40-48] via solid phase peptide synthesis (HTSCL-sC18; Scheme 1). We discuss the complex formation with Pt(II) and their detailed characterisation using NMR, MS, UV-vis absorption spectroscopy, electrochemical methods and DFT calculations. Finally, for selected compounds we present details about their stability in biological conditions, and their anti-proliferative activity towards human cancer and non-cancerous cells.



Scheme 1. Compounds in this study and their nomenclature.

Results and Discussion

Accepted Manuscrip

Syntheses of the HTSCmB protoligands, lysine derivatives HTSCLp, and the conjugate HTSCLsC18

S-benzyl methylamine isothiocyanate was synthesised by reacting the amine with CS₂ followed by a tosylchloride mediated decomposition derived from a method reported by Wong et al.[50] (Scheme 2A, details in the Experimental Section in the Supporting Information, SI). Upon reaction with hydrazine, the thiosemicarbazide was obtained in excellent yields (99%). The thiosemicarbazide was then reacted with three different *N*-heterocyclic carbonyls (Scheme 2B) to yield the three HTSCmB derivatives (analytical details and characterisation including single crystal XRD in the SI). The HTSCmB molecules were soluble in solvents like THF, MeCN and MeOH but not in H₂O.



Scheme 2. Multi-step synthesis of the (*S*)-*N*4-(α -methylbenzyl)thiosemicarbazone ligands (HTSCmB) with NMR nomenclature.

L-Lysine was converted into *t*-butyl-(*t*-butoxycarbonyl)-*L*-lysine (Scheme 3) in four-steps in an overall yield of 52% using using standard procedures (Scheme 3; details see SI). The amino function of the boc-protected lysine was converted into the isothiocyanate which was then reacted with hydrazine hydrate yielding the corresponding thiosemicarbazide. Condensation with the pyridine carbonyls yielded the HTSCLp protoligands (Lp stands for *protected lysine*) in overall yields of 23, 36, and 37%, respectively (Scheme 3).



Scheme 3. Synthesis of the protected lysine HTSCLp ligands (with NMR nomenclature).

Then, the boc-protected 2-(2-pyridyl)thiosemicarbazone-lysine derivative HdpyTSCLp was prepared for peptide coupling using a sequence of de-protection and re-protection steps (Scheme 4, details in the SI). Meanwhile, sC18 was synthesised by solid-phase peptide synthesis (SPPS) as previously described.[51] Subsequently, HdpyTSCL was coupled to the *N*-terminus of sC18 using a mixture of HATU/DIPEA (O-(7-azabenzotriazol-1-yl)-*N*,*N*,*N'*,*N'*-tetramethyluronium-hexafluorphosphate/*N*,*N*-diisopropyl-ethyl-amine) as activating reagents. Finally, the resulting conjugate was cleaved from the resin with concentrated trifluoroacetic acid and purified, yielding HdpyTSCL-sC18 in high purity of >95% (Scheme 4). HdpyTSCL-sC18 was characterised using HPLC and ESI-MS(+) (Figure S1, SI).



Scheme 4. Synthesis of the HdpyTSCL-sC18 peptide conjugate from HdpyTSCLp (SPPS: solid phase peptide synthesis).

Synthesis and characterisation of the Pt(II) complexes

In a next set of reactions, we let react all of the different protoligands HTSCmB and HTSCLp with K₂PtCl₄ using either organic solvents or aqueous solutions, respectively. Notably, the complexes [Pt(TSC)Cl] in very short reaction times and excellent yields.

Syntheses and characterisation of the "model" complexes [Pt(fpyTSCmB)Cl], [Pt(apyTSCmB)Cl], [Pt(dpyTSCmB)Cl] and [Pt(dpyTSCmB)(CN)]. The three [Pt(TSCmB)Cl] complexes (Schemes 1 and 2) were obtained from MeCN reaction mixtures in about 30 min with yields ranging from 93 to 97%. The CN complex was synthesised in 81% yield after workup through mixing a MeCN solution of the Cl derivative with an aqueous solution of KCN. NMR data and the crystal structure of the complexes [Pt(apyTSCmB)Cl] and [Pt(dpyTSCmB)(CN)] (two independent molecules in the unit cell) (Figure 1) proved a square planar coordination of Pt(II) through the deprotonated TSC ligand (N^NSthiolate) and a chlorido or cyanido coligand, respectively. The two experimental structures show C–S bond lengths

in the range of a single bond, whereas the C8–N3 lengths lie in the typical range of a double bond (Table 1) in line with already reported data and related structures.[10,24,25,27,29] A closer look at the angles around Pt(II) reveal distorted planar coordination with almost perfect Cl/C21–Pt–N2 angles of about 175 and 176°. However, the N1–Pt–N2 and N2–Pt–S bite angles of the five-membered chelates, which are markedly smaller than 90°, resulted in S–Pt–N1 angles of 166° and 165°. Furthermore, *trans* influence of the stronger CN⁻ coligand compared with Cl⁻ might be the reason for the elongated Pt–N2 bond length of about 2.00 Å in [Pt(dpyTSCmB)(CN)] (Table S20) compared with 1.966(5) found for the complex [Pt(apyTSCmB)CI] (Table 1).



Figure 1. Molecular structures of [Pt(dpyTSCmB)(CN)] (A, one out of two independent molecules) and [Pt(apyTSCmB)Cl] (B) from single crystal XRD; atoms shown with 50% probability and H atoms omitted for clarity. DFT calculated molecular structure of [Pt(dpyTSCmB)Cl] (C) at B3LYP def2-TZVP level (C,H,N,S,Cl) and B3LYP LANL2DZ level with ecp60 Hay & Wadt (Pt).[52,53]

The experimental and DFT calculated metrical parameters of [Pt(apyTSCmB)Cl] were essentially the same (Table 1, and SI). Only the distances in the ligand backbone vary slightly between the experimental and theoretical values. This might be the result of overestimation of the conjugation of the TSC system. On the other hand the DFT optimised structure represents the geometry in the gas phase, while the XRD data has been obtained from the crystalline solid in which bond lengths and angles might be modified by crystal packing. From this we concluded that suitable basis-sets to model the Pt complexes were found.

bond lengths / Å	XRD a	DFT ^b	angles / °	XRD a	DFT ^b
Pt–Cl	2.3173(2)	2.34	N1-Pt-N2	80.2(2)	80.69
Pt–N1	2.055(6)	2.07	N2-Pt-S	85.75(2)	84.79
Pt-N2	1.966(5)	1.99	S-Pt-Cl	96.75(6)	98.52
Pt–S	2.2623(2)	2.33	Cl-Pt-N1	97.35(2)	96.01
C10-N2	1.293(9)	1.34	Cl-Pt-N2	175.23(1)	176.88
N2-N3	1.391(8)	1.34	N1-Pt-S	166.05(1)	165.32
N3-C8	1.317(1)	1.34			
C8-S	1,775(8)	1.77	Σ of angles Pt	360.05(3)	360.01

Table 1. Selected experimental and DFT-calculated bond lengths and angles of [Pt(apyTSCmB)Cl].^a

^a From single crystal XRD data measured at 100(2) K, solved in orthorhombic *P* 212121; full crystallographic and metric date in the SI. ^b DFT calculations on B3LYP def2-TZVP level (for C,H,N,S,Cl) and B3LYP LANL2DZ level with ecp60 Hay & Wadt (for Pt).[51,52]

Cyclic voltammograms (CV) of [Pt(dpyTSCmB)Cl] recorded in MeCN (Figure 2) showed two fully reversible one-electron reduction waves at $E_{1/2} = -1.6$ V and -2.25 V, and a further irreversible wave at $E_{pc} = -2.9$ V (not shown). On the anodic scan an irreversible oxidation is observed at $E_{pa} = 0.74$ V. For the apy and fpy derivatives very similar values were observed (Figure S16-S18, Table S24, SI). For the [Pt(dpyTSCmB)(CN)] complex the oxidation is markedly anodically shifted (+0.23 V) compared with the Cl derivative, while the reduction potential is only slightly shifted (+0.1 V) (Figure S18, Table S24, SI). When taking a conversion factor of 0.62 V,[54] the two dpyTSCmB complexes are stable within a range from 0.1 (0.33 for CN) to approx. –2.1 V vs. NHE. In conclusion, the complexes were stable in a range of more than 2 V, giving hope for adequate redox stability in water and other biological conditions.



Figure 2. Cyclic voltammetry of [Pt(dpyTSCmB)Cl] in 0.1 M *n*-Bu₄NPF₆/MeCN solution at 100 mV/s scan rate. Square wave voltammograms in black, cathodic CV waves in blue, anodic waves in red.

We have seen that for [Pt(dpyTSCmB)Cl] the DFT-calculated highest occupied molecular orbital (HOMO) was located on the Pt(II) atom (d_{xy} orbital) and on the thiolate S atom and also obtained a minor contribution from the chlorido coligand (Figure 3). The electrochemical oxidation at 0.74 V can thus be attributed to a Pt(II)/Pt(III) redox pair with contributions from a thiolate(S⁻)/thiyl-radical(S[•]) pair. This is completely consistent with the observed anodic shift when changing the weak Cl⁻ coligand for the strong CN⁻. The lowest unoccupied molecular orbital (LUMO) had essentially the character of the lowest pyridine π^* orbital extending into the TSC backbone (Figure 3, Figure S19, SI). Thus, the first electrochemical reduction was directed into this orbital (ligand-centred).



Figure 3. DFT-calculated composition of LUMO and HOMO for [Pt(dpyTSCmB)Cl] at B3LYP def2-TZVP level (C,H,N,S,Cl) and B3LYP LANL2DZ level with ecp60 Hay & Wadt (Pt). Iso-surface level at 0.06.

The UV-vis absorption spectra of the four Pt(II) TSCmB complexes are all quite similar (Figure 4 and Figures S13 and S14, data in Table S23, SI). We assign the long-wavelength absorption to metal(d)-to-ligand(π^*) (MLCT) excited states based on our DFT calculations, while the UV bands were of π - π^* type and were also observed in the protoligands HTSCmB (Figures 4, S13 and S14, Table S23, SI).



Figure 4. UV-vis absorption spectra of HdpyTSCmB (blue), [Pt(dpyTSCmB)Cl] (black), and [Pt(dpyTSCmB)(CN)] (red) in MeCN.

When comparing complex [Pt(dpyTSCmB)(CN)] with the Cl derivative we recognised for the CN complex a slight blue-shift for the long-wavelength MLCT band and the absorptions at around 400 and 320 nm received changes in intensity and resolution (Figure 4). We assigned these changes to the stronger σ -donating and π -accepting CN ligand stabilising the metal-centred HOMO. Notably, this data was consistent with the observed markedly higher oxidation and slightly higher reduction potentials, as well as the DFT results.

Upon cathodic reduction of [Pt(dpyTSCmB)Cl] in 0.1 M *n*-Bu₄NPF₆/MeCN solution, a narrow unstructured EPR signal of approximate axial symmetry was observed in glassy frozen solution at 110 K (Figure 5 inset). The missing hyperfine splitting to the ¹⁹⁵Pt isotope ($I = \frac{1}{2}$, 33.8 % nat. abundance)

pointed to a negligible contribution of Pt orbitals to the singly occupied molecular orbital (SOMO). The g_{\perp} and g_{\parallel} values at 2.0066 and 2.0079 supported the ligand centred character.[54-58] At ambient *T* no signal was observed. Efforts to get EPR spectra of oxidised species were not successful.

Spectroelectrochemical UV-vis absorption measurements on cathodic scans showed the growth of a strong and broad absorption band centred at 490 nm for the first reduction step obscuring the long-wavelength MLCT band (Figure 5). Furthermore, the two π - π * absorption bands at 400 and 330 nm moved to 380 and 260 nm, respectively. Importantly, this process is fully reversible; the spectrum of the parent compound (green line in Figure 5) can be fully recovered upon anodic back-scan. The spectroscopic changes are strongly indicative for a singly reduced pyridine moiety indicating a ligand-centred reduction, and were thus, fully in line with our DFT calculations and related examples.[55-60]



Figure 5. UV-vis absorption spectra recorded during the first reduction of [Pt(dpyTSCmB)Cl] in 0.1 M *n*-Bu₄NPF₆/MeCN solution (0.05 V increments). Inset: X-band EPR spectrum recorded during the first reduction of [Pt(dpyTSCmB)Cl] (cathodic reduction in 0.1 M *n*-Bu₄NPF₆/MeCN solution at 298 K, measured at 110 K).

The second reduction process shows the formation of new long-wavelength bands between 550 nm and 800 nm as well as a hypochromic shift of the bands at 490 and 340 nm (Figure S20, SI) and turns out to be not reversible on the timescale of this experiment (5-20 min).

Syntheses and characterisation of the complexes [Pt(fpyTSCLp)Cl], [Pt(apyTSCLp)Cl], and [Pt(dpyTSCLp)Cl] containing protected lysin (Lp). The reaction of the boc-protected HTSCLp protoligands and K₂PtCl₄ was carried out in a mixture of MeCN and water. After 2 h stirring at ambient temperature and column chromatographic purification the three complexes were obtained in 75-87% yield. Good solubility of [Pt(apyTSCLp)Cl] in organic solvents allowed ¹⁹⁵Pt,¹H HMBC NMR experiments showing several ^xJ_{Pt-H} couplings between Pt and the TSC ligand backbone (Figure 6, Table S22, SI). The complexes were not soluble in water.



Figure 6. 300 MHz ¹⁹⁵Pt, ¹H HMBC NMR spectra of [Pt(apyTSCLp)Cl] in DMSO-d₆.

Since the UV-vis absorption spectra (Figure S13, Table S23, SI) as well as the redox behaviour (Figure S18, Table S24, SI) of the [Pt(TSCLp)Cl] complexes are very similar to those of the α -methyl benzyl (TSCmB) derivatives, we supposed the same complex entity [Pt(N^N^S)Cl]. Moreover, we did not observe any influence on the photophysical and electrochemical properties of the complexes when changing the side residue from α -methyl benzyl to protected lysine.

Syntheses and characterisation of the Pt conjugate complexes [Pt(dpyTSCL-sC18)Cl] and [Pt(dpyTSCL-sC18)(CN)]. The conjugate protoligand HdpyTSCL-sC18 was reacted with K₂PtCl₄ in H₂O for 2 h at ambient T forming the complex [Pt(dpyTSCL-sC18)Cl]. The crude complex was desalted using a C18ec cartridge (Chromafix C18ec, Macherey-Nagel), evaporated from solvent and lyophilised. HPLC analysis and ESI-MS confirmed quantitative product formation, while unreacted HdpyTSCL-sC18 was not observed (Figure 7).



Figure 7. HPLC analysis (left) and ESI-MS(+) analysis (right) of [Pt(dpyTSCL-sC18)Cl] after desalting. Detected masses for $[M+nH]^{n+}$ are labelled in blue, the calculated mass for [Pt(dpyTSCL-sC18)Cl] is 2666.40 (found: 2666.26). Detected masses for $[M-Cl+nH]^{(n+1)+}$ are labelled in black representing the

complex [Pt(dpyTSCL-sC18)]⁺ without coordinated chloride. For [M–Cl]⁺ 2631.43 were calculated, 2630.47 were found.

The ESI-MS analysis showed the target complex [Pt(dpyTSCL-sC18)Cl] alongside with the species $[Pt(dpyTSCL-sC18)]^+$ having lost the chloride coligand. The UV-vis absorption spectrum of the product proved the quantitative formation of a [Pt(N^N^S)Cl] complex as shown before for the other TSC ligand derivatives (Figure S21, S13-S15, SI). Interestingly, changing from organic solvents to water did not lead to alterations of the long-wavelength MLCT band energy. The observed energy fitted well into the solvatochromic behaviour recorded for the [Pt(dpyTSCLp)Cl] complexes which is in good correlation to the Reichardt E_T(30) solvent parameters[61] (Figure S22, SI).

Complex [Pt(dpyTSCL-sC18)(CN)] was synthesised in 2 h from KCN, HdpyTSCL-sC18 and K₂PtCl₄ in quantitative yield. HPLC analysis and ESI-MS(+) of the purified complex showed exclusively the product (Figure 8). In this case, the species [Pt(dpyTSCL-sC18)]⁺ having lost the anionic coligand was not observed. This observation underlined the stronger binding of the CN⁻ coligand to Pt compared to Cl⁻.



Figure 8. HPLC analysis and ESI-MS(+) analysis of [Pt(dpyTSCL-sC18)(CN)] conjugate after desalting. The sample was recorded using a linear gradient from 10-60% MeCN in H₂O (incl. 0.1% trifluoroacetic acid) within 15 min. The identified molecular ions agree well with the calculated molecular weight (calculated: 2657.44 g/mol; experimental: 2659.13 g/mol).

The stability of [Pt(dpyTSCL-sC18)Cl] and [Pt(dpyTSCL-sC18)(CN)] was tested for 72 h in fetal bovine serum (FBS) containing medium using UV-vis absorption spectroscopy (Figure S23, SI). The long-wavelength MLCT band of the complexes was used as an indicator for structural integrity. During the first hours, a decay of about 2% of the [Pt(dpyTSCL-sC18)Cl] complex was observed, but no further changes were detected (Figure S23, SI). Compared to this, a loss of 19% signal intensity was observed for [Pt(dpyTSCL-sC18)(CN)] (Figure S23, SI).

Anti-proliferative activity

Next, we investigated the anti-proliferative activity of several of our TSC ligands, as well as their Pt(II) complexes (Figure 9). As control we included Dp44mT (di-2-pyridylketone-4,4,-dimethyl-3-thiosemicarbazone, Figure S24, SI), which is structurally very similar to HdpyTSCmB,[19,20,62-65] the We chose two different cancer cell lines, namely breast adenocarcinoma MCF-7 (Michigan Cancer Foundation 7) and colorectal carcinoma HT-29 cells, since those have been already used in former experiments, thus allowing for comparing the activity or our novel compounds with recent results from our own studies and literature.[44-46,66-70] HEK-293 (embryonic kidney) cells were used as non-cancerous control cell line (Figure 9).

HdpyTSCmB exhibited quite strong anti-proliferative activity against HT-29 cells, while MCF-7 cells were less harmed (Figure 9A, B). However, also HEK-293 cells were strongly affected (Figure 9C) letting assume only less selectivity of this compound. Overall, the activity was in the range of Dp44mT [72-75] and DpC (di-2-pyridylketone-4-cyclohexyl-4-methyl-3-thiosemicarbazone).[18-20] Notably, the Pt complexes [Pt(dpyTSCmB)Cl] and [Pt(dpyTSCmB)(CN)] exhibited reduced activity compared with the ligand alone. Only at high concentrations of 10-25 µM markedly reduced cell viability was observed. Thereby it seemed that the CN complex was more active against HT-29 cells, while the Cl derivative demonstrated higher activity against HEK cells. Interestingly, there was no difference detectable when incubating the complexes with MCF-7 cells. Recently, it was hypothesised that TSC molecules coordinate in the cell to redox-active metals such as Fe or Cu, and that these formed complexes would lead to the production of reactive oxygen species, damaging the cell.[8,15,20,63-65,71-75] In fact, this would explain also our observation of higher activity of the free ligands compared with the Pt complexes. Obviously, Pt(II) is only a poor substitute to these redox-active metals that are known to quickly react with H2O2 forming hydroxyl radicals in Fenton-type reactions.[63-65,71-75]. Considering that we have measured high electrochemical stability for both Pt model complexes [Pt(dpyTSCmB)Cl] and [Pt(dpyTSCmB)(CN)], particularly against reduction, would further substantiate our assumption.



Figure 9. Anti-proliferative activity of HdpyTSCmB, [Pt(dpyTSCmB)Cl] and [Pt(dpyTSCmB)(CN)] against MCF-7 (A), HT-29 (B) and HEK-293 (C) cells after incubating them for 72 h with different concentrations of the compounds. Anti-proliferative activity of sC18, HdpyTSCLp, HdpyTSCL-sC18, [Pt(dpyTSCL-sC18)Cl], and [Pt(dpyTSCL-sC18)(CN)] against MCF-7 (D), HT-29 (E) and HEK-293 (F). Cells treated with 70% EtOH served as a positive control. Data were normalised to untreated cells (100% viability). Shown are mean ± SD values of three independent experiments, each performed in triplicate.

12

ChemBioChem

compounds for 72 h with the three cell lines (Figure 9D, E, F). In fact, the non-complexed HdpyTSCLsC18 showed a significant anti-proliferative activity compared to the parent peptide sC18 when applied at 25 µM to MCF-7 (p=0.0449) or HT-29 (p=0.0226) cells. Surprisingly, the ligand HdpyTSCLp alone only exhibited significant toxicity towards HEK-293 cells (p=0.0058), also when at the highest concentration studied. For the corresponding platinum complexes, exclusively [Pt(dpyTSCL-sC18)Cl] was determined to significantly reduce the cell viability of HT-29 (p=0.0200) and HEK-293 (p=0.0409) cells when added at 25 µM. That sC18 did not display cytotoxic effects agrees to already published results and demonstrates again that sC18 is well-tolerated.[43,47,51]. For the other tested substances including the HdpyTSCL-sC18 ligand and the complex [Pt(dpyTSCL-sC18)Cl], we found this more surprising. However, since we have already demonstrated that sC18 is a highly efficient carrier for various cargos, including also metal complexes, [42-48,51] we were very confident that the whole conjugate entered the cells. The results let rather concluded that there might be a dramatic influence of the linker structure that bridges the TSC with the carrier molecule (in this case sC18). This hypothesis is probably proven by the observation that we did also not detect any activity of HdpyTSCLp being structurally highly divers to recently reported toxic binuclear Pt(II)Cl complexes containing triazolebridged bisthiosemicarbazone ligands.[10] In addition, we have already seen similar effects when coupling Rh(III) polypyridyl complexes to sC18.[44] Generally, the potency of such metal complexes is often dependent on specific properties like DNA intercalation. For sC18 conjugates it is already known that they are mainly taken up by endocytotic pathways, restricting efficient cytosolic release, and thus, transfer of the cargo to its final target.[43,47] One way to overcome this limitation is to include specific proteolytic cleavage sites within the ligand to peptide structure, e.g. for cathepsin B. This protease is abundant in the lysosomes and may induce enhanced endosomal release.[42]

Interestingly, no or only minor decrease in cell viability was determined after incubating all other

On the other side, the good tolerability of the novel Pt(II) conjugates paves the way for future studies, in which we will use these and related Pt-TSC-peptide conjugates for late-stage radiolabelling with Pt radionuclides , such as ¹⁸⁹Pt, ¹⁹¹Pt, ^{193m}Pt, and ^{195m}Pt that are very interesting candidates for Auger-electron radionuclide therapy.[76-79] The advantage of this method is the emission of low energy electrons which are able to ionise material in a very confined space, thus reducing radiation damage to healthy cells.[80,81] Tagged by a ligand containing biological information, the radionuclide can be transported to a desired location or cell, thus focussing the decay and cell damage in a certain area (targeted radiotherapy). The facile, rapid and stable binding of Pt(II) from a simple source such as K₂PtCl₄ together with the observed high stability and virtual non-toxicity make our systems very suitable for late-stage labelling.

Conclusions

L-lysine-based thiosemicarbazone (TSC) ligands were successfully conjugated to the cell-penetrating peptide sC18, using standard solid phase peptide synthesis. The overall synthesis yield for the peptide conjugate is 10% over 10 steps. The tridentate N^N^S binding site in of the pyridine-based TSC bound rapidly and quantitatively to Pt(II) forming Pt chlorido complexes of the type [Pt(TSC)Cl]. This was shown for dpyTSCL-sC18 as well as for model compounds with N4-(α -methylbenzyl) termination (TSCmB) or protected L-lysinate (TSCLp). Increasing the terminating chain from dpyTSCmB to dpyTSCL-sC18 drastically enhanced their solubility. The sC18 conjugated Pt complexes [Pt(dpyTSCLsC18X with X = Cl or CN were soluble in solvents ranging from rather non-polar CH₂Cl₂ to water. The uncoordinated HdpyTSCmB showed antiproliferative activity towards the human cancer cell lines MCF-7 and HT-29 as well as the non-cancer cell line HEK-293. For the two non-conjugated Pt complexes containing this ligand [Pt(dpyTSCmB)X] (X = Cl or CN) the activity was markedly reduced and only for the HEK cells IC50 values lower than 25 µM were found. Interestingly, none of the sC18conjugated compounds as well as HdpyTSCLp exhibited significant anti-proliferative activities. Future studies will be directed to get unequivocal proof that the conjugates have entered the cells. In summary, we highlighted these non-toxic and biologically very stable Pt(II) complexes as very interesting candidates for a late stage labelling with the radioisotopes ¹⁸⁹Pt, ¹⁹¹Pt, ^{193m}Pt, or ^{195m}Pt.

Experimental Section

Materials and syntheses

The syntheses of the three HTSCmB protoligands and the boc-protected lysine derivatives HTSCLp are outlined in detail in the Supporting Information (SI).

Synthesis of the Pt complexes [Pt(TSCmB)Cl] – general description

The protoligands HTSCmB and K₂[PtCl₄] were dissolved in MeCN and stirred for 2 h at ambient temperature. The colour changes from yellow to dark red. Upon evaporation of the solvent a red solid forms, which was isolated by filtration.

[Pt(fpyTSCmB)Cl]. Yield: 119.9 mg (0.23 mmol, 97%). C₁₅H₁₅ClN₄PtS (513.90) C: 35.06, H 2.94, N: 10.90, S: 6.24. Found C: 35.03, H: 3.02, N: 10.90, S 6.29%. ¹H NMR: (300 MHz, DMSO-d₆) δ = 8.87 (d, 1H, *J* = 8.0 Hz, *N*H), 8.70 (d, 1H, *J* = 5.6 Hz, ³*J*_{PH} = 27 Hz, HPy6), 8.35 (s, 1H, ³*J*_{PH} = 12 Hz H_{im}), 8.13 (t, 1H, *J* = 7.7 Hz, HPy4), 7.70 (t, 1H, *J* = 7.9 Hz, HPy5), 7.33 (d, 5H, *J* = 5.9 Hz, H3,4,5), 7.25 (dd, 1H, *J* = 6.1, 2.1 Hz,

HPy3), 5.06 (quint, 1H, *J* = 7.4 Hz, H1), 1.42 (d, 3H, *J* = 7.1 Hz, H6) ppm (nomenclature as in Scheme 2) EI-MS(+) m/z = 514 [M]⁺, 478 [M-Cl]⁺.

[Pt(apyTSCmB)Cl]. Yield: 0.121 g (0.23 mmol, 96%). Anal. Calc. for C₁₆H₁₇ClN₄PtS (527.93) C: 36.40, H 3.25, N: 10.61, S: 6.07. Found C: 36.39, H: 3.24, N: 10.60, S 6.08%. ¹H NMR: (300 MHz, DMSO-d₆) δ = 8.76 (m, 2H, *N*H7, ³*J*_{PH} = 16 Hz, HPy6), 8.16 (t, 1H, *J* = 7.9 Hz, HPy4), 7.74 (d, 1H, *J* = 8.1 Hz, HPy5), 7.68 (d, 1H, *J* = 6.8 Hz, HPy3), 7.41-7.29 (m, 4H, H3,4), 7.24 (m, 1H, H5), 5.13-4.93 (m, 1H, H1), 2.26 (d, 3H, *J* = 6.9 Hz, CH_{3im}), 1.43 (d, 3H, *J* = 7.0 Hz, H6) ppm. EI-MS(+) m/z = 528 [M]⁺, 492 [M-Cl]⁺.

[Pt(dpyTSCmB)Cl]. Yield: 0.131 g (0.22 mmol, 93%). Anal. Calc. for C₂₀H₁₈ClN₅PtS (590.99) C: 40.65, H 3.07, N: 11.85, S: 5.42. Found C: 40.66, H: 3.08, N: 11.88, S 5.41 %. ¹H NMR: (300 MHz, DMSO-d₆) δ = 9.02 (d, 1H, *J* = 7.2 Hz, NH7), 8.84 (d, 1H, *J*_{HH} = 5.0 Hz, ³*J*_{PtH} = 27 Hz, HPy6), 8.72 (d, 1H, *J* = 4.9 Hz HPy′6), 8.06 (d, 1H, *J* = 5.0 Hz, HPy4), 7.97 (t, 1H, *J* = 4.9 Hz, HPy′4), 7.70 (t, 1H, *J* = 7.4 Hz, HPy5), 7.60 (t, 1H, *J* = 7.5 Hz, HPy′5), 7.45 (d, 1H, *J* = 7.9 Hz, HPy3), 7.40-7.15 (m, 5H, H3, H4, H5), 7.36 (d, 1H, *J* = 7.9 Hz, HPy′3), 4.65 (quint, 1H, *J* = 6.9 Hz, H1), 1.32 (d, 3H, *J* = 7.0 Hz, 3H, H6) ppm. EI-MS(+) m/z = 591 [M]⁺, 555 [M-Cl]⁺.

Synthesis of [Pt(dpyTSCmB)(CN)]. 65 mg (0.11 mmol) of [Pt(dpyTSCmB)Cl] were dissolved in 5 mL MeCN. 20 mg (0.3 mmol) KCN were dissolved in 1 mL H₂O of which 0.5 mL were added to the complex solution. The mixture rapidly changed colour from a dark red to bright red. After 2 h at room temperature, the solvent was removed and the crude mixture was purified by silica column chromatography (100% EtOAc). A bright red/pinkish band was isolated containing the desired complex. Yield: 46 mg (0.081 mmol, 81%). C₂₁H₁₈N₆PtS (581.55). ¹H NMR (300 MHz, DMSO-d₆) δ = 9.19 (d, 1H, *J* = 7.1 Hz, NH7), 8.85 (d, 1H, *J* = 5.4 Hz, ³*J*_{PtH} = 35 Hz, HPy6), 8.77 (d, 1H, *J* = 4.9 Hz, HPy'6), 8.10 (t, 1H, *J* = 8.0 Hz, HPy4), 7.99 (t, 1H, *J* = 7.2 Hz, HPy'4), 7.66 (t, 1H, *J* = 7.7, 1.8 Hz, HPy5'), 7.59 (t, 1H, *J*_{HH} = 7.8 Hz, HPy5), 7.49 (m, 1H, HPy'3), 7.44 (m, 1H, HPy3), 7.35-7.19 (m, 3H, H4,5), 7.04 (d, 2H, *J* = 8.1 Hz, H3), 4.77-4.62 (m, 1H, H1), 1.34 (d, 3H, *J* = 7.0 Hz, H6) ppm. EI-MS(+) m/z = 581 [M]⁺.

Synthesis of the Pt complexes [Pt(TSCLp)Cl] – general description

1 eq. of the ligand was dissolved in MeCN and added to a solution of 1 eq. K₂[PtCl₄]. The colour changes from yellow to dark red. After 2 h the solvent was evaporated under reduced pressure and the residue was purified by column chromatography.

[Pt(fpyTSCLp)Cl]. Yield: 127 mg (0.18 mmol, 75%). Anal. Calc. for C₂₂H₃₄ClN₅O₄PtS (695.13) C: 38.01, H 4.93, N: 10.07, S: 4.61. Found C: 38.02, H: 4.95, N: 10.09, S 4.60 %. ¹H NMR: (300 MHz, DMSO-d₆) δ = 8.72 (d, 1H, *J* = 5.3 Hz, ³*J*_{PtH} = 24 Hz, HPy6), 8.40 (s, 1H, ³*J*_{PtH} = 12 Hz, H_{im}), 8.30 (d, 1H, *J* = 4.5 Hz, HPy3), 8.15 (t, 1H, *J* = 8.2 Hz, HPy4), 7.71 (t, 1H, *J* = 9.0 Hz, HPy5), 7.08 (d, 1H, *J* = 7.8 Hz, NH7), 5.07 (d, 1H, *J* = 8.3 Hz, NH), 3.75 (q, 2H, *J* = 6.7 Hz, H1), 3.65-3.55 (m, 1H, H5), 1.69-1.47 (m, 4H, H3,4), 1.39 (m, 20H, H2,9,10,11,13,14,15) ppm (nomenclature as in Scheme 3). EI-MS(+) m/z = 695 [M]⁺, 659 [M-Cl]⁺, 465 [HfpyTSCLp]⁺.

[Pt(apyTSCLp)Cl]. Yield: 141 mg (0.2 mmol, 83%). Anal. Calc. for C23H36ClN5O4PtS (709.16) C: 38.95, H 5.12, N: 9.88, S: 4.52. Found C: 38.98, H: 5.12, N: 9.87, S 4.55 %. ¹H NMR: (300 MHz, CDCl₃) δ = 8.88 (d, 1H, J = 5.5 Hz, ³J_{PtH} = 14 Hz, HPv6), 7.90 (t, 1H, J = 7.6 Hz, HPv4), 7.78 (d, 1H, , J = 9.0 Hz, HPv3), 7.69 (d, 1H, J = 6.7 Hz, HPy5), 7.07 (d, 1H, J = 8.3 Hz, NH7), 4.24-4.01 (m, 1H, H5), 3.47 (q, 2H, J = 6.7 Hz, H1), 2.29 (s, 3H, CH3im), 1.86-1.52 (m, 6H, H2,3,4), 1.45 (s, 9H, H13,14,15), 1.43 (s, 9H, H9,10,11) ppm. $^{1}H/^{195}$ Pt-HMBC NMR: (300 MHz, CDCl₃) $\delta = -3108$ ($^{3}J_{Pt-HPy6} = 14$ Hz, $^{4}J_{Pt-HCH3}$ obscured, $^{5}J_{Pt-HPy4} = 21$ Hz) ppm. HR-ESI-MS(+): m/z calculated [M+Na]⁺: 732.17167; found: 732.16964. FTIR-ATR: v [cm⁻¹] 3853 (w), 3675 (m), 3424 (w), 2987 (s), 2901 (s), 2359 (w), 1715 (m), 1558 (w), 1507 (m), 1455 (m), 1406 (m), 1394 (m), 1380 (m), 1250 (m), 1230 (m), 1154 (m), 1075 (s), 1066 (s), 1056 (s), 1028 (m), 891 (w), 789 (w), 706 (w), 642 (w), 626 (w), 618 (m), 606 (m), 591 (w), 581 (w), 570 (w), 560 (w), 546 (w), 540 (w), 526 (w). [Pt(dpyTSCLp)Cl]. Yield: 162 mg (0.21 mmol, 87%). Anal. Calc. for C27H37ClN6O4PtS (772.22) C: 42.00, H 4.83, N: 10.88, S: 4.15. Found C: 42.02, H: 4.82, N: 10.90, S 4.15 %. ¹H NMR: (300 MHz, CDCl₃) δ = 8.90 (d, 1H, J = 5.6 Hz, ³J_{PH} = 15 Hz, HPy6), 8.75 (d, 1H, J = 4.7 Hz, HPy'6), 8.08 (td, 1H, J = 7.9, 1.6 Hz, HPy4), 7.98 (td, 1H, J = 7.8, 1.7 Hz, HPy'4), 7.85 (d, 1H, J = 7.9 Hz, HPy3), 7.73 (td, 1H, J = 7.9, 4.1 Hz, HPy'5), 7.53 (m, 1H, HPy5), 7.43 (d, 1H, J = 8.1 Hz, HPy'3), 7.06 (d, 1H, J = 7.7 Hz, NH7), 4.03 (quint, 1H, J = 7.1 Hz, H5), 3.16 (d, 2H, J = 6.4 Hz, H1), 1.49 (m, 6H, J = 7.4 Hz, H2,3,4), 1.38 (d, 18H, J = 3.0 Hz, H9,10,11,13,14,15) ppm.HR-ESI-MS(+): m/z calculated [M+Na]⁺: 795.18271; found: 795.18364.

Synthesis of HdpyTSCL-sC18. sC18 (Gly-Leu-Arg-Lys-Arg-Leu-Arg-Lys-Phe-Arg-Asn-Lys-Ile-Lys-Glu-Lys-NH₂) was synthesised as previously described.[51] HdpyTSCL (15 μ mol, 2 eq) was coupled manually to the resin using 2 eq HATU (O-(7-azabenzotriazol-1-yl)-*N*,*N*,*N'*,*N'*-tetramethyluronium hexafluorophosphate) and 2 eq DIPEA (*N*,*N*-diisopropylethylamine) in DMF for 2 h at r.t. The resulting HdpyTSCL-sC18 conjugate was cleaved from the resin with trifluoroacetic acid/triisopropylsilane/H₂O (95/2.5/2.5, v/v/v) and precipitated in ice cold diethyl ether. Then it was purified by preparative HPLC (column: Nucleodur C18ec; 100-5; Macherey-Nagel; solvent: 10-60% MeCN in H₂O (incl. 0.1% TFA) over 45 min, 6.0 mL/min flow rate). The product was identified via HPLC-ESI MS (column: Nucleodur C18ec; 100-5; Macherey-Nagel; gradient: 10-60% MeCN in H₂O (incl. 0.1% formic acid) over 15 min; 0.6 mL/min flow rate). After purification a yield of 19.7 mg (8.08 μ mol, 53.8%) was determined.

Synthesis of [Pt(dpyTSCL-sC18)Cl]. 500 mL 5 mM stock solution of HdpyTSCL-sC18 in H₂O were added to 250 μ L of a freshly prepared 10 mM aqueous solution of K₂PtCl₄ (41.5 mg in 10 mL) and incubated for 2 h under shaking at r.t. The complex formation reaction was UV-vis monitored through the absorption at 500 nm. The crude complex was desalted using a C18ec cartridge (Chromafix C18ec,

Macherey-Nagel), solvent was evaporated and the red residue lyophilised. The product was analysed by ESI-MS(+) (Figure 7 and Figure S2, SI) and UV-vis absorption spectroscopy (Figure S21, SI).

Synthesis of [Pt(dpyTSCL-sC18)(CN)]. 75 μL of a 10 mM aqueous KCN solution (6.52 mg in 10 mL) were added to a 500 μL 1 mM stock solution of HdpyTSCL-sC18 and incubated under shaking for 1 h at r.t. Then, 50 μL aqueous K₂PtCl₄ solution (4.15 mg in 1 mL) was added and the reaction mixture incubated for 1 h at r.t. The complex formation was UV-vis monitored through the absorption at 500 nm. The crude complex was desalted using a C18ec cartridge (Chromafix C18ec, Macherey-Nagel), solvent was evaporated and the red residue lyophilised. Figure 8 shows HPLC analysis and ESI-MS(+) spectrum of [Pt(dpyTSCL-sC18)CN]. Final HPLC chromatogram was recorded using a linear gradient from 10-60% MeCN in H₂O (incl. 0.1% trifluoroacetic acid) within 15 min (Nucleodur C18ec; 100-5 (Macherey-Nagel) column (1 mL/min flow rate)). UV-vis absorption spectroscopy in Figure S21, SI.

Instrumentation

NMR spectra were recorded on a Bruker Avance II 300 MHz spectrometer, using a triple resonance ¹H, ⁿBB inverse probe head. The unambiguous assignment of the ¹H and ¹³C resonances was obtained from 1H NOESY, ¹H COSY, gradient selected ¹H, ¹³C HSQC and ¹H, ¹⁹⁵Pt HMBC experiments. All 2D NMR experiments were performed using standard pulse sequences from the Bruker pulse program library. Chemical shifts were relative to TMS (¹H, ¹³C) or H₂PtCl₆ (¹⁹⁵Pt). UV-vis absorption spectra were measured using a Varian 50 Scan UV-visible photometer. EPR spectra were recorded in the Xband on a Bruker System ELEXSYS 500E equipped with a Bruker Variable Temperature Unit ER 4131VT (500 to 100 K); the g values were calibrated using a dpph sample. Electrochemical experiments were carried out in 0.1 M n-Bu₄NPF₆ solutions using a three-electrode configuration (glassy carbon working electrode, Pt counter electrode, Ag/AgCl pseudo reference) and an Autolab PGSTAT30 potentiostat and function generator. Experiments were run at a scan rate of 100 mV/s, at ambient temperature and the ferrocene/ferrocenium couple served as internal reference. UV-vis spectroelectrochemical measurements were performed with an optical transparent thin-layer electrochemical (OTTLE) cell.[82,83] EI-MS(+) spectra were recorded on a Thermo Quest Finnigan MAT 95 at 70 eV. HR-ESI-MS(+) spectra were measured at the Thermo Scientific LTQ Orbitrap XL mass spectrometer via electron spray ionisation and a FTMS Analyzer. IR spectra were obtained on a Si crystal Fourier-Transform spectrometer by Thermo Scientific (Nicolet 380 FT-IR).

Crystal structure determination

The measurements were performed at 293(2) K on IPDS II (STOE and Cie.) or at 100(2) K on a Bruker Apex II, both using graphite-monochromatised Mo-K α radiation (λ = 0.71073 Å). These structures were solved by direct methods using SHELX-97 and WinGX (SHELXS-97)[84-86] and refined by full-matrix least-squares techniques against F^2 (SHELXL-2017/1).[87,88] The numerical absorption

Accepted Manuscript

corrections (X-RED V1.22; Stoe & Cie, 2001) were performed after optimising the crystal shapes using X-SHAPE V1.06 (Stoe & Cie, 1999).[89,90] The non-hydrogen atoms were refined with anisotropic displacement parameters. H atoms were included by using appropriate riding models. Further measurements were performed on SC-XRD Bruker D8 Venture at 100(2) K in kappa geometry equipped with a copper micro focus source and a Photon100 detector, or at the beamline P24 of the synchrotron PETRA III at DESY in Hamburg, Germany. These structures were resolved using OLEX2 and refined by charge flipping.[91] CCDC: 1954934 (HfpyTSCmB), 1954950 (HapyTSCmB), 1954933 (HdpyTSCmB·MeOH), 1954935 ([Pt(apyTSCmB)Cl]), and 2022743 ([Pt(dpyTSCmB)(CN)]), contain the These obtained full crystallographic data. data can be free of charge at www.ccdc.cam.ac.uk/conts/retrieving.html or from the Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge, CB2 1EZ UK. Fax: +44-1223-336-033; Email: deposit@ccdc.cam.ac.uk.

Quantumchemical DFT calculations

DFT-calculations on the geometries, were carried out on def-SV(P)[92]/B3LYP[93-95] level using the TURBOMOLE[96] program package and TmoleX user interface.[97] HOMO and LUMO energies were calculated on def2-TZVP[98]/B3LYP level for H, C, N, S, and Cl atoms and LANL2DZ[99]/B3LYP with ecp60 Hay&Watt[52,53] for Pt.

Peptide conjugates

The cell-penetrating peptide was synthesised by automated solid phase peptide synthesis on a Syro I peptide synthesiser (MultiSynTech). HPLC chromatograms were recorded on an Agilent 1260 HPLC system (column: Nucleodur C18ec; 100-5; Macherey-Nagel; gradient: 10-60% MeCN in water (incl. 0.1 % formic acid) over 15 min; 0.6 mL/min flow rate). ESI-MS(+) spectra were recorded on a LTQ-XL mass spectrometer via electron spray ionisation (Thermo Scientific). Data was evaluated with XcaliburTM Software (Thermo Scientific).[100]

Antiproliferative activities

Antiproliferative activity was determined by photospectrometric measurements. The conversion of resazurin (λ_{ex} = 550 nm) into the resorufin product (λ_{ex} = 595 nm) was measured [101] on a Tecan infinite M200 plate reader (Tecan Group AG). Data were normalised to untreated control cells were (100% viability). Statistical analysis was performed via Mircosoft Excel T-test with 2 tails, type 2 (two-sample, equal variances).

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

Prof. Dr. Mathias Wickleder and Dr. Daniel Werner, Institute for Inorganic Chemistry, Department of Chemistry, University of Cologne are gratefully acknowledged for the beamline time at DESY. Prof. Dr. Mathias Schäfer, Department of Chemistry, University of Cologne is thanked for HR-ESI-MS measurements and Prof. Dr. Bernd Neumaier, Department of Chemistry, Institute for Nuclear Chemistry, Cologne University Clinics, Institute of Radiochemistry, and Research Center Jülich for financial support and consulting. We also like to thank the Regional Computing Center of the University of Cologne (RRZK) for providing computing time on the DFG-funded High Performance Computing (HPC) system CHEOPS as well as for the support. Tamara Lützenburg acknowledges financial support by the Jürgen-Manchot Stiftung.

References

- [1] T. S. Lobana, R. Sharma, G. Bawa S. Khanna, Bonding and structure trends of thiosemicarbazone derivatives of metals—An overview, *Coord. Chem. Rev.*, 2009, **253**, 977–1055.
- [2] Pelosi, G. Thiosemicarbazone Metal Complexes: From Structure to Activity. *Open Cryst. J.* **2010**, *3*, 16–28.
- [3] M. Christlieb, J. R. Dilworth, Ligands for Molecular Imaging: The Synthesis of Bis(thiosemicarbazone) Ligands. *Chem.–Eur. J.* **2006**, *12*, 6194–6206.
- [4] M. M. Subarkhan, R. Ramesh, Binuclear ruthenium(III) bis(thiosemicarbazone) complexes: Synthesis, spectral, electrochemical studies and catalytic oxidation of alcohol, *Spectrochim. Acta A*, 2015, 138, 264–270.
 [5] P. Pelagatti, A. Venturini, A. Leporati, M. Carcelli, M. Costa, A. Bacchi, G. Pelizzi, C. P
- [5] P. Pelagatti, A. Venturini, A. Leporati, M. Carcelli, M. Costa, A. Bacchi, G. Pelizzi C. Pelizzi, Chemoselective homogeneous hydrogenation of phenylacetylene using thiosemicarbazone and thiobenzoylhydrazone palladium (II) complexes as catalysts, *J. Chem. Soc., Dalton Trans.*, 1998, 2715–2722.
- [6] L. C. Matsinha, J. Mao, S. F. Mapolie and G. S. Smith, Water-Soluble Palladium(II) Sulfonated Thiosemicarbazone Complexes: Facile Synthesis and Preliminary Catalytic Studies in the Suzuki–Miyaura Cross-Coupling Reaction in Water, *Eur. J. Inorg. Chem.*, 2015, 2015, 4088– 4094.
- [7] J. R. Dilworth, R. Hueting, Metal complexes of thiosemicarbazones for imaging and therapy. *Inorg. Chim. Acta* 2012, 389, 3–15.
 [8] B. M. Paterson, P. S. Donnelly, Copper complexes of bis(thiosemicarbazones): From
- [8] B. M. Paterson, P. S. Donnelly, Copper complexes of bis(thiosemicarbazones): From chemotherapeutics to diagnostic and therapeutic radiopharmaceuticals. *Chem. Soc. Rev.* 2011, 40, 3005–3018.
- [9] A. L. Vāvere, J. S. Lewis, Cu–ATSM: A radiopharmaceutical for the PET imaging of hypoxia, *Dalton Trans.*, **2007**, *43*, 4893–4902.
- [10] A. I. Matesanz, J. M. Herrero, Eva J. Faraco, L. Cubo, A. G. Quiroga, New Platinum(II) Triazole Thiosemicarbazone Complexes: Analysis of Their Reactivity and Potential Antitumoral Action, *ChemBioChem* 2020, 21, 1226-1232.
- [11] A. G. Quiroga, C. N. Ranninger, Contribution to the SAR field of metallated and coordination complexes. Studies of the palladium and platinum derivatives with selected thiosemicarbazones as antitumoral drugs. *Coord. Chem. Rev.* **2004**, *248*, 118–133.
- [12] A. G. Quiroga, J. M. Pérez, I. López-Solera, J. R. Masaguer, A. Luque, P. Román, A. Edwards, C. Alonso, C. Navarro-Ranninger, Novel Tetranuclear Orthometalated Complexes of Pd(II) and Pt(II) Derived from *p*-Isopropylbenzaldehyde Thiosemicarbazone with Cytotoxic Activity in cis-DDP Resistant Tumor Cell Lines. Interaction of These Complexes with DNA, *J. Med. Chem.* 1998, 41, 1399–1408.
- [13] J. Easmon, G. Pürstinger, G. Heinisch, T. Roth, H. H. Fiebig, W. Holzer, W. Jäger, M. Jenny, J. Hofmann, Synthesis, Cytotoxicity, and Antitumor Activity of Copper(II) and Iron(II) Complexes of 4N-Azabicyclo[3.2.2]nonane Thiosemicarbazones Derived from Acyl Diazines, J. Med. Chem., 2001, 44, 2164–2171.
- [14] A. Gatti, A. Habtemariam, I. Romero-Canelón, J.-I. Song, B. Heer, G. J. Clarkson, D. Rogolino, P. J. Sadler, M. Carcelli, Half-Sandwich Arene Ruthenium(II) and Osmium(II) Thiosemicarbazone Complexes: Solution Behavior and Antiproliferative Activity, *Organometallics*, **2018**, *37*, 891–89.

- [15] Pelosi, G.; Bisceglie, F.; Bignami, F.; Ronzi, P.; Schiavone, P.; Re, M.C.; Casoli, C.; Pilotti, E. Antiretroviral Activity of Thiosemicarbazone Metal Complexes. J. Med. Chem. 2010, 53, 8765– 8769.
- [16] C. G. Oliveira, I. Romero-Canelón, M. M. Silva, J. P. C. Coverdale, P. I. S. Maia, A. A. Batista, S. Castelli, A. Desideri, P. J. Sadler, V. M. Deflon, Palladium(II) complexes with thiosemicarbazones derived from pyrene as topoisomerase IB inhibitors, Dalton Trans. 2019, 48, 16509-16517.
- [17] F. Salsi, G. B. Portapilla, K. Schutjajew, M. R. Jungfer, A. Goulart, A. Hagenbach, S. de Albuquerque, U. Abram, Anti-Parasitic Complexes Organometallic Gold(III) Complexes with Tridentate Halogen-Substituted Thiosemicarbazones: Effects of Halogenation on Cytotoxicity and Anti-Parasitic Activity, Eur. J. Inorg. Chem. 2019, 2019, 4455–4462. [18] R. Ettari, F. Bova, M. Zappala, S. Grasso, N. Micale, Falcipain-2 Inhibitors. Med. Res. Rev.
- **2010**, 30, 136–167
- [19] S. N. Maqbool, S. C. Lim, K. C. Park, R. Hanif, D. R. Richardson, P. J. Jansson, Z. Kovacevic, Overcoming tamoxifen resistance in oestrogen receptorpositive breast cancer using the novel thiosemicarbazone anticancer agent, DpC, *Br. J. Pharmacol.* **2020**, 2020, 1–16.
- [20] P. J. Jansson, D. S. Kalinowski, D. J. R. Lane, Z. Kovacevic, N. A. Seebacher, L. Fouani, S. Sahne, A. M. Merlot, D. R. Richardson, The renaissance of polypharmacology in the development of anti-cancer therapeutics: Inhibition of the "Triad of Death" in cancer by Di-2-pyridylketone thiosemicarbazones. Pharmacol. Res. 2015, 100, 255-260.
- [21] M. Raudenska, J. Balvan, M. Fojtu, J. Gumulec, M. Masarik, Unexpected therapeutic effects of cisplatin, *Metallomics*, 2019, 11, 1182–1199.
 [22] P. V Simpson, N. M. Desai, I. Casari, M. Massi, M. Falasca, Metal-based antitumor
- compounds: beyond cisplatin, Future Med. Chem. 2019, 11, 119–135.
- [23] R. G. Kenny, C. J. Marmion, Toward Multi-Targeted Platinum and Ruthenium Drugs A New Paradigm in Cancer Drug Treatment Regimens?, *Chem. Rev.* **2019**, *119*, 1058–1137. [24] A. I. Matesanz, I. Leitao, P. Souza, Palladium(II) and platinum(II) bis(thiosemicarbazone)
- complexes of the 2,6-diacetylpyridine series with high cytotoxic activity in cisplatin resistant
- A2780cisR tumor cells and reduced toxicity, *J. Inorg. Biochem.*, **2013**, 125, 26–31. [25] A. I. Matesanz, C. Hernandez, A. Rodriguez, P. Souza, Novel bis(thiosemicarbazones) of the 3,5-diacetyl-1,2,4-triazol series and their platinum(II) complexes: chemistry, antiproliferative activity and preliminary nephrotoxicity studies, *Dalton Trans.*, **2011**, 40, 5738–5745.
- [26] J. Patole, S. Padhye, M. S. Moodbidri, N. Shirsat, Antiproliferative activities of iron and platinum conjugates of salicylaldehyde semi-/thiosemicarbazones against C6 glioma cells, Eur. J. Med. Chem., **2005**, 40, 1052–1055.
- [27] D. Kovala-Demertzi, A. Galani, N. Kourkoumelis, J. R. Miller, M. A. Demertzis, Synthesis, characterization, crystal structure and antiproliferative activity of platinum(II) complexes with 2-acetylpyridine-4-cyclohexyl-thiosemicarbazone, Polyhedron, 2007, 26, 2871–2879.
- [28] D. Kovala-Demertzi, A. Boccarelli, M. A. Demertzis, M. Coluccia, In vitro Antitumor Activity [20] D. Rovala Denertzi, R. Deceren, M. P. Denertzis, M. Colaccia, in vitro Infittement Incurvity of 2-Acetyl Pyridine 4N-Ethyl Thiosemicarbazone and Its Platinum(II) and Palladium(II) Complexes, *Chemotherapy*, **2007**, 53, 148–152.
 [29] D. Kovala-Demertzi, M. A. Demertzis, J. R. Miller, C. Papadopoulou, C. Dodorou, G.
- Filousis, Platinum(II) complexes with 2-acetyl pyridine thiosemicarbazone: Synthesis, crystal structure, spectral properties, antimicrobial and antitumour activity, J. Inorg. Biochem. 2001, 86, 555-563
- [30] M. D. Hall, K. A. Telma, K.-E. Chang, T. D. Lee, J. P. Madigan, J. R. Lloyd, I. S. Goldlust, J. D. Hoeschele, M. M. Gottesman, Say No to DMSO: Dimethylsulfoxide Inactivates Cisplatin,
- Carboplatin and Other Platinum Complexes, *Canc. Res.* 2014, 74, 3919–3922.
 [31] M. Salmain, N. Fischer-Durand, B. Rudolf, Bioorthogonal Conjugation of Transition Organometallic Complexes to Peptides and Proteins: Strategies and Applications, *Eur. J.* Inorg. Chem. 2020, 2020, 21-35.
- [32] O. Desiatkina, E. Păunescu, M. Mösching, N. Anghel, G. Boubaker, Y. Amdouni, A. Hemphill, J. Furrer, Coumarin-Tagged Dinuclear Trithiolato-Bridged Ruthenium(II)-Arene Complexes – Photophysical Properties and Antiparasitic Activity, ChemBioChem 2020, accepted manuscript. DOI:10.1002/cbic.202000174.
- [33] Q.-P. Qin, Z.-F. Wang, X.-L. Huang, M.-X. Tan, Z.-H. Luo, S.-L. Wang, B.-Q. Zou, H. Liang, Two telomerase-targeting Pt(II) complexes of jatrorrhizine and berberine derivatives induce
- [34] Z. Xu, C. Li, Q. Zhou, Z. Deng, Z. Tong, M.-K. Tse, G. Zhu, Synthesis, Cytotoxicity, and Mechanistic Investigation of Platinum(IV) Anticancer Complexes Conjugated with Poly(ADPribose) Polymerase Inhibitors, *Inorg. Chem.* 2019, 58, 16279–16291.
- [36] A. Zamora, A. Gandioso, A. Massaguer, S. Buenestado, C. Calvis, J. L. Hernandez, F. Mitjans, V. Rodriguez, J. Ruiz, V. Marchan, Toward Angiogenesis Inhibitors Based on the Conjugation of Organometallic Platinum(II) Complexes to RGD Peptides, *ChemMedChem.*, 2018, 13, 1755-1762.

- [37] A. I. Solomatina, P. S. Chelushkin, D. V. Krupenya, I. S. Podkorytov, T. O. Artamonova, V. V. Sizov, A. S. Melnikov, V. V. Gurzhiy, E. I. Koshel, V. I. Shcheslavskiy, S. P. Tunik, Coordination to Imidazole Ring Switches on Phosphorescence of Platinum Cyclometalated Complexes: The Route to Selective Labeling of Peptides and Proteins via Histidine Residues, Bioconjugate Chem. 2017, 28, 426-437.
- [38] B. Albada, N. Metzler-Nolte, Highly Potent Antibacterial Organometallic Peptide Conjugates, Acc. Chem. Res. 2017, 50, 2510–2518.
- [39] D. Śmiłowicz, N. Metzler-Nolte, Synthesis of monofunctional platinum(IV) carboxylate precursors for use in Pt(IV)–peptide bioconjugates, *Dalton Trans.* **2018**, 47, 15465–15476. [40] S. Abramkin, S. M. Valiahdi, M. A. Jakupec, M. Galanski, N. Metzler-Nolte, B. K. Keppler,
- Solid-phase synthesis of oxaliplatin-TAT peptide bioconjugates, Dalton Trans., 2012, 41, 3001-3005.
- [41] I. Neundorf, Metal Complex-Peptide Conjugates: How to Modulate Bioactivity of Metal-Containing Compounds by the Attachment to Peptides, Curr. Med. Chem. 2017, 24, 1853-1861.
- [42] L. Feni, S. Parente, C. Robert, S. Gazzola, D. Arosio, U. Piarulli, I. Neundorf, Kiss and Run: Promoting Effective and Targeted Cellular Uptake of a Drug Delivery Vehicle Composed of an Integrin-Targeting Diketopiperazine Peptidomimetic and a Cell-Penetrating Peptide, *Bioconjugate Chem.* **2019**, 30, 2011–2022.
- [43] I. Neundorf, R. Rennert, J. Hoyer, F. Schramm, K. Lobner, I. Kitanovic, S. Wolfl, Fusion of a
- [45] I. Neuhaon, R. Kehnert, J. Hoyer, P. Schhamm, R. Eobher, T. Khanović, S. Wolf, Fusion of a Short HA2-Derived Peptide Sequence to Cell-Penetrating Peptides Improves Cytosolic Uptake, but Enhances Cytotoxic Activity, *Pharmaceuticals*, 2009, 2, 49–65.
 [44] Y. Geldmacher, K. Splith, I. Kitanović, H. Alborzinia, S. Can, R. Rubbiani, M. A. Nazif, P. Wefelmeier, A. Prokop, I. Ott, S. Wölfl, I. Neundorf, W. S. Sheldrick, Cellular impact and selectivity of half-sandwich organorhodium(III) anticancer complexes and their complexes and their complexes and their selectivity. organoiridium(III) and trichloridorhodium(III) counterparts, J. Biol. Inorg. Chem., 2012, 17, 631–646
- [45] W. Hu, K. Splith, I. Neundorf, K. Merz, U. Schatzschneider, Influence of the metal center and linker on the intracellular distribution and biological activity of organometal-peptide
- [46] K. Splith, I. Neundorf, W. Hu, H. W. P. N'Dongo, V. Vasylyeva, K. Merz, U. Schatzschneider, Influence of the metal complex-to-peptide linker on the synthesis and properties of bioactive CpMn(CO)3 peptide conjugates, Dalton Trans. 2010, 39, 2536–2545.
- [47] A. Gronewold, M. Horn, I. Randelovic, J. Tovari, S. Munoz Vazquez, K. Schomacker, I. Neundorf, Characterization of a Cell-Penetrating Peptide with Potential Anticancer Activity, *ChemMedChem* **2017**, *12*, 42–49.
- [48] A. Gronewold, M. Horn, I. Neundorf, Design and biological characterization of novel cell-[10] In Groneword, In Horiz, In Healthory, Design and Diological characterization of Robel centre penetrating peptides preferentially targeting cell nuclei and subnuclear regions, *Beilstein J. Org. Chem.* 2018, 14, 1378–1388.
 [49] A. Isidro-Llobet, M. Álvarez, F. Albericio, Amino Acid-Protecting Groups, *Chem. Rev.* 2009,
- 109, 2455–2504
- [50] R. Wong, S. J. Dolman, Isothiocyanates from Tosyl Chloride Mediated Decomposition of in Situ Generated Dithiocarbamic Ácid Salts, J. Org. Chem. **2007**, 72, 3969–3971.
- [51] M. Horn, I. Neundorf, Design of a novel cell-permeable chimeric peptide to promote wound healing, *Sci. Rep.* 2018, *8*, 16279–16279.
 [52] P. J. Hay, W. R. Wadt, "Ab initio effective core potentials for molecular calculations potentials for the transition-metal atoms Sc to Hg," *J. Chem. Phys.* 1985, *82*, 270–283.
- [53] P. J. Hay, W. R. Wadt, Ab initio effective core potentials for molecular calculations -
- potentials for K to Au including the outermost core orbitals, *J. Chem. Phys.* 1985, *82*, 299–310.
 [54] N. G. Connelly, W. E. Geiger, Chemical Redox Agents for Organometallic Chemistry, *Chem. Rev.* 1996, *96*, 877–910.
- [55] S. Sobottka, M. Nößler, A. L. Ostericher, G. Hermann, N. Z. Subat, J. Beerhues, M. Behr-van der Meer, L. Suntrup, U. Albold, S. Hohloch, J. C. Tremblay, B. Sarkar, Tuning Pt^{II}-Based Donor–Acceptor Systems through Ligand Design: Effects on Frontier Orbitals, Redox Potentials, UV/Vis/NIR Absorptions, Electrochromism, and Photocatalysis, *Chem.–Eur. J.* 2020, 26, 1314-1327
- [56] E. Bulak, T. Varnali, B. Schwederski, B. Sarkar, I. Hartenbach, J. Fiedler, W. Kaim, 2,3-Bis(1methylimidazol-2-yl)quinoxaline (bmiq), a new ligand with decoupled electron transfer and metal coordination sites: the very different redox behaviour of isoelectronic complexes with [PtCl₂] and [AuCl₂]⁺, *Dalton Trans.* **2011**, *40*, 2757–2763.
- [57] S. Roy, I. Hartenbach, B. Sarkar, Structures, Redox and Spectroscopic Properties of Pd^{II} and
- Pt^{II} Complexes Containing an Azo Functionality, *Eur. J. Inorg. Chem.* 2009, 2553–2558.
 [58] W. Kaim, A. Dogan, M. Wanner, A. Klein, I. Tiritiris, T. Schleid, D. J. Stufkens, T. L. Snoeck, E. J. L. McInnes, J. Fiedler, S. Záliš, Reduced and Excited States of (bpym)[PtCl₂]ⁿ (bpym = 2,2'-Bipyrimidine; n = 1, 2): Experiments and DFT Calculations, *Inorg. Chem.* 2002, 41, 4139– 4148.
- [59] A. Klein, E. J. L. McInnes, W. Kaim, Organometallic platinum(II) complexes of methylsubstituted phenanthrolines, J. Chem. Soc., Dalton Trans. 2002, 2371–2378.

- [60] L. S. Jongbloed, N. Vogt, A. Sandleben, B. de Bruin, A. Klein, J. I. van der Vlugt, Nickel-Alkyl Complexes with a Reactive PNC-Pincer Ligand, Eur. J. Inorg. Chem., 2018, 2018, 2408– 2418. [61] C. Reichardt, Solvatochromic Dyes as Solvent Polarity Indicators, *Chem. Rev.* **1994**, *94*, 2319–
- 2358.
- [62] S. Krishan, S. Sahni, L. Y. W. Leck, P. J. Jansson, D. R. Richardson, Regulation of autophagy and apoptosis by Dp44mT-mediated activation of AMPK in pancreatic cancer cells, Biochim.
- Biophys. Acta, Mol. Basis Dis. 2020, 1866, 165657 (1–17).
 [63] D. S. Kalinowski, C. Stefani, S. Toyokuni, T. Ganz, G. J. Anderson, N. V. Subramaniam, D. Trinder, J. K. Olynyk, A. Chua, P. J. Jansson, S. Sahni, D. J.R. Lane, A. M. Merlot, Z. Kovacevic, M. L.H. Huang, C. S. Lee, D. R. Richardson, Redox cycling metals: Pedaling their production of the second seco roles in metabolism and their use in the development of novel therapeutics, *Biochim. Biophys. Acta* 2016, 1863, 727–748.
 [64] P. J. Jansson, T. Yamagishi, A. Arvind, N. Seebacher, E. Gutierrez, A. Stacy, S. Maleki, D.
- Sharp, S. Sahni, D. R. Richardson, Di-2-pyridylketone 4,4-Dimethyl-3-thiosemicarbazone (Dp44mT) Overcomes Multidrug Resistance by a Novel Mechanism Involving the Hijacking
- (b) Pilliti') Overcomes inducted g residuce by a reor incention interning the rindering of Lysosomal P-Glycoprotein (Pgp)*, J. Biol. Chem. 2015, 290, 9588–9603.
 [65] D. J. R. Lane, T. M. Mills, N. H. Shafie, A. M. Merlot, R. S. Moussa, D. S. Kalinowski, Z. Kovacevic, D. R. Richardson, Expanding horizons in iron chelation and the treatment of cancer: Role of iron in the regulation of ER stress and the epithelial-mesenchymal transition,
- Biochim. Biophys. Acta 2014, 1845, 166–181.
 [66] C. Cullinane, G. B. Deacon, P. R. Drago, A. P. Erven, P. C. Junk, J. Luu, G. Meyer, S. Schmitz, I. Ott, J. Schur, L. K. Webster, A. Klein, Synthesis and Antiproliferative Activity of a Series of 1020 New Platinum and Palladium Diphosphane Complexes, Dalton Trans. 2018, 47, 1918–1932.
- [67] V. Lingen, A. Lüning, A. Krest, G. B. Deacon, J. Schur, I. Ott, I. Pantenburg, G. Meyer, A. Klein, Labile Pd-Sulphur and Pt-Sulphur Bonds in Organometallic Palladium and Platinum Complexes [(COD)M(alkyl)(S-ligand)]ⁿ⁺ - A speciation study, J. Inorg. Biochem. 2016, 165, 119-127.
- [68] A. Lüning, M. Neugebauer, V. Lingen, A. Krest, K. Stirnat, G. B. Deacon, P. R. Drago, I. Ott, J. Schur, I. Pantenburg, G. Meyer, A. Klein, Platinum Diolefin Complexes - Synthesis,
- Schur, I. Fantenburg, G. Meyer, A. Richt, Flatman Diolenn Complexes Synthesis, Structures and Cytotoxicity, *Eur. J. Inorg. Chem.* 2015, 2015, 226–239.
 [69] A. Lüning, J. Schur, L. Hamel, I. Ott, A. Klein, Strong Cytotoxicity of Organometallic Platinum Complexes with Alkynyl Ligands, *Organometallics* 2013, 32, 3662–3672.
 [70] J. Schur, A. Lüning, A. Klein, R. W. Köster, I. Ott, Platinum alkynyl complexes: Cellular uptake, inhibition of thioredoxin reductase and toxicity in zebrafish embryos, *Inorg. Chim.* 4, 2010, 405–118082 (1–5).
- Acta, 2019, 495, 118982 (1–5). [71] A. Gaála, G. Orgován, V. G. Mihucz, I. Pape, D. Ingerle, C. Streli, N. Szoboszlai, Metal transport capabilities of anticancer copper chelators, J. Trace Elem. Med. Biol. **2018**, 47, 79-88.
- [72] F. N. Akladios S. D. Andrew, C. J. Parkinson, Cytotoxic activity of expanded coordination bis -thiosemicarbazones and copper complexes thereof, *J. Biol. Inorg. Chem.* **2016**, *21*, 931–944. [73] A. Gaál, V. G. Mihucz, S. Bösze, I. Szabó, M. Baranyi, P. Horváth, C. Streli, N. Szoboszlai,
- Comparative in vitro investigation of anticancer copper chelating agents, Microchem. J. 2016, 136, 227–235.
- [74] E. Potuckova, H. Jansova, M. Machacek, A. Vavrova, P. Haskova, L. Tichotova, V. Richardson, D. S. Kalinowski, D. R. Richardson, T. Simunek, Quantitative Analysis of the Anti-Proliferative Activity of Combinations of Selected Iron-Chelating Agents and Clinically
- Used Anti-Neoplastic Drugs, *PloS One* 2014, 9, e88754 (1–15).
 [75] D. B. Lovejoy, P. J. Jansson, U. T. Brunk, J. Wong, P. Ponka, D. R. Richardson, Antitumor Activity of Metal-Chelating Compound Dp44mT Is Mediated by Formation of a Redox-Active Copper Complex That Accumulates in Lysosomes, *Cancer Res.* **2011**, *71*, 5871–5880. [76] E. Boros, A. B. Packard, Radioactive Transition Metals for Imaging and Therapy, *Chem. Rev.*
- **2019**, 119, 870-901.
- [77] J. A. O'Donoghue, T. E. Wheldon, Targeted radiotherapy using Auger electron emitters, *Phys. Med. Biol.* **1996**, *41*, 1973–1992.
- [78] H. Obata, M. U. Khandaker, E. Furuta, K. Nagats, M.-R. Zhang, Excitation functions of proton- and deuteron-induced nuclear reactions on natural iridium for the production of ¹⁹¹Pt, *Appl. Radiat. Isot.* **2018**, 137, 250–260.
- [79] S. M. Qaim, Nuclear data for production and medical application of radionuclides: Present status and future needs, *Nucl. Med. Biol.* 2017, 44, 31–49.
 [80] F. Buchegger, F. Perillo-Adamer, Y. M. Dupertuis, A. Bischof Delaloye, Auger radiation
- targeted into DNA: a therapy perspective, *Eur. J. Nucl. Med. Mol. Imaging* **2006**, *33*, 1352–1363.
- [81] S. M. Qaim, I. Spahn, Development of novel radionuclides for medical applications, J. Label. Compd. Radiopharm. **2018**, 61, 126–140.
- [82] W. Kaim, J. Fiedler. Spectroelectrochemistry: the best of two worlds. Chem. Soc. Rev. 2009, 38, 3373-3382
- [83] W. Kaim, A. Klein (eds.), Spectroelectrochemistry, RSC Publishing Cambridge, UK, 2008.
- [84] G. M. Sheldrick, A short history of SHELX. Acta Crystallogr., Sect. A: Found. Crystallogr. 2008, 64, 112–122
- [85] G. M. Sheldrick, SHELX-97, Programs for Crystal Structure Analysis, Göttingen, 1997.
- [86] L. J. Farrugia, WinGX and ORTEP for Windows: an update. J. Appl. Cryst. 2012, 45, 849–854.

- [87] G. M. Sheldrick, SHELXL-2017/1, Program for the Solution of Crystal Structures, University of Göttingen, Germany, 2017.
- [88] G. M. Sheldrick, Crystal structure refinement with SHELXL. Acta Crystallogr., Sect. C: Struct. Chem. 2015, 71, 3–8.
- [89] STOE X-RED, Data Reduction Program, Version 1.22/Windows, STOE & Cie, Darmstadt, 2001.
- [90] STOE X-SHAPE, Crystal Optimisation for Numerical Absorption Correction, Version 1.06/Windows, STOE & Cie, Darmstadt, 1999.
- [91] O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. K. Howard, H. Puschmann, OLEX2: a complete structure solution, refinement and analysis programm, J. Appl. Cryst. 2009, 42, 339-341.
- [92] A. Schäfer, H. Horn and R. Ahlrichs, Fully Optimized Contracted Gaussian-Basis Sets for Atoms Li to Kr. J. Chem. Phys. 1992, 97, 2571–2577.
 [93] C. T. Lee, W. T. Yang and R. G. Parr, Development of the Colle-Salvetti Correlation-Energy
- Formula into a Functional of the Electron-Density, Phys. Rev. B 1988, 37, 785-789.
- [94] A. D. Becke, A new mixing of Hartree-Fock and local density-functional theories. J. Chem. Phys. 1993, 98, 1372–1377.
- [95] A. D. Becke, Density-functional thermochemistry. III. The role of exact exchange. J. Chem. Phys. 1993, 98, 5648–5652
- [96] TURBOMOLE 7.0, TURBOMOLE GmbH 2015.
- [97] C. Steffen, K. Thomas, U. Huniar, A. Hellweg, O. Rubner, A. Schroer, TmoleX-a graphical user interface for TURBOMOLE. J. Comput. Chem. 2010, 31, 2967–2970.
- [98] F. Weigend, R. Ahlrichs, Balanced basis sets of split valence, triple zeta valence and quadruple zeta valence quality for H to Rn: Design an assessment of accuracy, *Phys. Chem. Chem. Phys.* **2005**, *7*, 3297–3305.
- [99] T. H. Dunning Jr., P. J. Hay, in Modern Theoretical Chemistry, Ed. H. F. Schaefer III, Vol. 3 (Plenum, New York, **1977**) 1-28.] Xcalibur™ Software, Data acquisition, Version 2.2/Windows, Thermo Scientific,
- [100] Darmstadt, Germany 2011.
- T. L. Riss, R. Moravec, A. Niles, H. Benink, T. Worzella, L. Minor, Cell Viability Assays. [101] Assay Guidance Manual 2004. 1–23.